Y Intercept Hong Kong Ltd Purchases 70,897 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Key Points

• Y Intercept Hong Kong Ltd significantly increased its stake in Dyne Therapeutics by purchasing an additional 70,897 shares, resulting in ownership of 80,665 shares and a portfolio value of $844,000.
• Dyne Therapeutics reported a loss of $1.05 per share for the latest quarter, falling short of analysts' estimates, with a projected EPS of -3.44 for the current fiscal year.
• Analysts have expressed positive outlooks for Dyne Therapeutics, with a consensus rating of "Moderate Buy" and an average target price of $40.63 despite fluctuating target estimates from various firms.

Y Intercept Hong Kong Ltd lifted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 725.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 80,665 shares of the company's stock after purchasing an additional 70,897 shares during the quarter. Y Intercept Hong Kong Ltd owned 0.07% of Dyne Therapeutics worth $844,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Janus Henderson Group PLC grew its holdings in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock valued at $173,808,000 after purchasing an additional 566,146 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Dyne Therapeutics by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock worth $44,476,000 after purchasing an additional 27,916 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $42,408,000. Orbimed Advisors LLC grew its holdings in shares of Dyne Therapeutics by 73.2% during the fourth quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company's stock worth $28,910,000 after purchasing an additional 518,680 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $22,384,000. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $9.95 on Friday. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $47.45. The business's 50 day moving average price is $10.93 and its two-hundred day moving average price is $11.78. The firm has a market cap of $1.13 billion, a PE ratio of -2.77 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity

In related news, CEO John Cox bought 100,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were bought at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer directly owned 242,179 shares of the company's stock, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.14% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on DYN shares. Raymond James Financial started coverage on shares of Dyne Therapeutics in a report on Wednesday, June 11th. They set an "outperform" rating and a $37.00 target price on the stock. Robert W. Baird reduced their target price on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a report on Wednesday, June 18th. Chardan Capital reissued a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Tuesday, June 17th. Oppenheimer started coverage on shares of Dyne Therapeutics in a report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price on the stock. Finally, JPMorgan Chase & Co. reduced their target price on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $40.63.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.